Rituximab dose-escalation trial in chronic lymphocytic leukemia.
about
The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaFludarabine in the treatment of chronic lymphocytic leukemia: a reviewObinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomasIdelalisib and rituximab in relapsed chronic lymphocytic leukemiaThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsOcaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemiaThe value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome.A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.Alemtuzumab for B-cell chronic lymphocytic leukemia.Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report.A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.Repeated courses of rituximab in chronic ITP: Three different regimens.A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLLFludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyPolyploidy in chronic lymphocytic leukemia with p53 deletion detected by fish: a case reportManagement of chronic lymphocytic leukemia.Rituximab: therapeutic benefit! Vitamin R?Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.Biologics and heart failure in rheumatoid arthritis: are we any wiser?A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphomaRole of bendamustine in the treatment of chronic lymphocytic leukemia.Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drugArsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Rituximab: mechanisms and applications.The spectrum of use of rituximab in chronic lymphocytic leukemiaRole of fludarabine in hematological malignancies.Role of rituximab in first-line treatment of chronic lymphocytic leukemia.Antibody therapy for chronic lymphocytic leukemia.Radioimmunotherapy for acute leukemia.Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
P2860
Q24617708-802B48AD-B2B6-4187-A4C7-905A494C22A4Q24645173-665BAD59-2117-4263-8AAC-1AB84C243C92Q26751002-F2FAB5CA-1ED2-493C-BA2D-CC57B503878FQ28306347-12436803-2E7B-4453-B5B1-C0603769D9CEQ30243968-C3803813-1B3D-4421-B23F-C37855436E52Q30411688-207C9C71-3173-4D68-836D-56CEE7D3DE9FQ30421637-306059A7-FE6C-44F5-B799-342E897033C2Q30577607-3DD833E8-E8F2-4CF0-8C6B-8EA35EB86FAEQ31033615-FA9B4533-7DCD-4909-AC8C-A046F6C81268Q33343951-5A4448AD-82D8-4DCE-9DDA-534D7D3DC11CQ33346607-1E59A26E-0E6E-4EDE-B6C4-F78F6A524885Q33380135-255417F1-945B-4E73-A458-A62678EF3E40Q33380747-DBE7A3D8-829E-4683-A147-559A43512E14Q33385566-813308F1-0F98-44E2-8464-80BA7CC8CE52Q33386117-B5C50B7F-51E7-4089-9601-01B088FFED6BQ33397239-1789943A-6A13-46FE-ADA7-E31C026467C4Q33406164-746AD1A1-7B11-4C31-8AE8-3996D7A9BBDDQ33418091-9C349295-678E-492C-B8A8-5BAA2DC72BCDQ33424781-F5EA3AE0-102E-4D74-81FA-97B6284A63D6Q33438428-EF951636-EF1A-47F3-A993-4B23D43CC8A4Q33681804-DF72140E-F01D-4942-8718-61CE2B399B2DQ33695912-DE9FF966-14D9-4399-AA68-1928D122698BQ33764056-8561BFD5-2B41-4AA5-A7D9-96417200266BQ33770207-3FCB1C2E-DCAE-4DB3-9CFD-BC7F84DCB5ECQ33880538-6B7EF26E-C1E9-4216-A92F-022AC5A25E0FQ33898103-2A97E134-DB93-4751-A38B-6CC5523E5F7FQ33905245-224E6389-F43F-4755-837A-3663D5EEA1A9Q33916026-AA18EDCC-CF1F-47E2-B12D-CD10D9FAE7FEQ34009003-FD310F2C-0A27-49F9-8934-0296468FEC93Q34065271-ACBCFD96-9502-4AD0-B0FE-2628A1C0A5DBQ34185125-6B19D807-8222-4723-9D0A-5DE409E737CCQ34310845-8EC2E2FA-6271-4C86-8330-6ED4702E3464Q34334943-1E255B1C-E09E-49CF-B5A7-A000453D0D43Q34462378-B1D5655F-1B1C-4111-BB8B-A78A2DBA88A8Q34510030-02EC0DEE-61A2-4CF3-9E57-3471CA6058B4Q34571439-E9BB82D2-17A1-4BA6-9F5D-367FC360EFB5Q34574147-8211D22F-6B48-49D6-9689-385327641847Q34589909-0ECBDF6D-2497-4DCC-9974-5984B7515FAAQ34608650-BE41A347-8ACD-4AF6-BD0C-DBAA925465A0Q34617307-859D38CB-237A-4786-93FF-C9317CD98CA7
P2860
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
@en
type
label
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
@en
prefLabel
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
@en
P2093
P1476
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
@en
P2093
D A Thomas
E J Freireich
H Kantarjian
M J Keating
S M O'Brien
P304
P356
10.1200/JCO.2001.19.8.2165
P407
P577
2001-04-01T00:00:00Z